These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19364050)

  • 61. How can we optimize treatment of HER2-positive metastatic breast cancer?
    Hamilton EP; Blackwell KL
    Oncology (Williston Park); 2013 Mar; 27(3):180, 182. PubMed ID: 23687786
    [No Abstract]   [Full Text] [Related]  

  • 62. [Chemotherapy and targeted drugs to reinforce each other].
    Foukakis T; Bergh J
    Lakartidningen; 2017 Feb; 114():. PubMed ID: 28221400
    [No Abstract]   [Full Text] [Related]  

  • 63. Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer.
    Aziz H; Marcom PK; Hwang ES
    Ann Surg Oncol; 2015 May; 22(5):1404-5. PubMed ID: 25777094
    [No Abstract]   [Full Text] [Related]  

  • 64. Practice-changing data in metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2013; 11(10 Suppl 16):7-12. PubMed ID: 24637555
    [No Abstract]   [Full Text] [Related]  

  • 65. HER2 and Breast Cancer - A Phenomenal Success Story.
    Hayes DF
    N Engl J Med; 2019 Sep; 381(13):1284-1286. PubMed ID: 31502769
    [No Abstract]   [Full Text] [Related]  

  • 66. HER2-directed treatment of metastatic breast cancer: unanswered questions.
    Rao R; Cobleigh M
    Oncology (Williston Park); 2013 Mar; 27(3):176, 178, 180. PubMed ID: 23687785
    [No Abstract]   [Full Text] [Related]  

  • 67. An update into the pathophysiological role of HER2 in cancer: therapeutic implications.
    Ocaña A; Pandiella A
    Clin Transl Oncol; 2007 Sep; 9(9):543-4. PubMed ID: 17921099
    [No Abstract]   [Full Text] [Related]  

  • 68. Neratinib Graduates to I-SPY 3.
    Cancer Discov; 2014 Jun; 4(6):624. PubMed ID: 24891343
    [No Abstract]   [Full Text] [Related]  

  • 69. Are current development programs realising the full potential of new agents?
    Lønning PE
    Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S23. PubMed ID: 21172086
    [No Abstract]   [Full Text] [Related]  

  • 70. A Comprehensive Review on the State of the Art of Breast Cancers in Italy.
    Iacopetta D; Ceramella J; Catalano A; Rosano C; Mariconda A; Giuzio F; Bonofiglio D; Saturnino C; Longo P; Sinicropi MS
    Curr Med Chem; 2024; 31(18):2486-2506. PubMed ID: 38213176
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Editorial: Targeted therapy for HER-2: personalized medicine for her, too.
    Melichar B; Plebani M
    Clin Chem Lab Med; 2012 Jan; 50(1):1-4. PubMed ID: 22505535
    [No Abstract]   [Full Text] [Related]  

  • 72. Symptom burden and quality of life among women with HER2(+) metastatic breast cancer.
    Mayer M; Lang K; Hurvitz S; Lalla D; Federico V; Brammer M; Menzin J; Tripathy D
    Breast J; 2015; 21(2):208-10. PubMed ID: 25655357
    [No Abstract]   [Full Text] [Related]  

  • 73. A multifunctional toolkit for target-directed cancer therapy.
    Terrazas M; Sánchez D; Battistini F; Villegas N; Brun-Heath I; Orozco M
    Chem Commun (Camb); 2019 Jan; 55(6):802-805. PubMed ID: 30574643
    [TBL] [Abstract][Full Text] [Related]  

  • 74. HER2-positive breast cancer: the story goes on.
    Chamberlin MD; Kaufman PA
    Oncology (Williston Park); 2014 Apr; 28(4):290, 292-3. PubMed ID: 24839798
    [No Abstract]   [Full Text] [Related]  

  • 75. Targeting HER2 by Combination Therapies.
    Ruiz-Saenz A; Moasser MM
    J Clin Oncol; 2018 Mar; 36(8):808-811. PubMed ID: 29381433
    [No Abstract]   [Full Text] [Related]  

  • 76. De-escalating and escalating systemic therapy of early breast cancer.
    Smith IE; Okines AFC
    Breast; 2017 Aug; 34 Suppl 1():S5-S9. PubMed ID: 28694014
    [No Abstract]   [Full Text] [Related]  

  • 77. Precise predictive and therapeutic strategy for breast cancer.
    Kyrochristos ID; Peristeri DV; Ziogas DE; Lykoudis EG; Roukos DH
    Future Oncol; 2018 Aug; 14(18):1777-1780. PubMed ID: 29846090
    [No Abstract]   [Full Text] [Related]  

  • 78. Apoptosis of breast cancer cells: modulation of genes for glycoconjugate biosynthesis and targeted drug delivery.
    Basu S; Ma R; Moskal JR; Basu M; Banerjee S
    Adv Exp Med Biol; 2012; 749():233-55. PubMed ID: 22695849
    [No Abstract]   [Full Text] [Related]  

  • 79. HER2 targeting in early breast cancer: more options and more questions.
    Lembersky BC; Rastogi P
    Oncology (Williston Park); 2014 Apr; 28(4):293-4. PubMed ID: 24839799
    [No Abstract]   [Full Text] [Related]  

  • 80. Are bilateral and unilateral interval breast cancers different?
    Altundag K
    J BUON; 2018; 23(3):836-837. PubMed ID: 30003762
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.